Anavex Life Sciences Corp AVXL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.82
- Day Range
- $2.56–2.82
- 52-Week Range
- $2.56–13.99
- Bid/Ask
- $2.63 / $2.90
- Shares Outstanding
- 92.67M
- Market Cap
- $238.17M
- Volume/Avg
- 942,449 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.anavex.com
Valuation
|
Metric
|
AVXL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.88 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVXL
|
|---|---|
Quick Ratio | 20.81 |
Current Ratio | 20.87 |
Interest Coverage | — |
Quick Ratio
AVXL
Profitability
|
Metric
|
AVXL
|
|---|---|
Return on Assets (Normalized) | −25.28% |
Return on Equity (Normalized) | −28.05% |
Return on Invested Capital (Normalized) | −32.22% |
Return on Assets
AVXL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Phgbmvrs | Gtjkx | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fnssbvbbq | Qhnqz | $67B | |||
| argenx SE ADR
ARGX
| Jwplhtjn | Fmjq | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jtsjqflts | Fbwypq | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Ntsdrddxbn | Mpjnyb | $25B | |||
| BioNTech SE ADR
BNTX
| Wyhhxmc | Knln | $22B | |||
| Incyte Corp
INCY
| Nryxmqynj | Nkfg | $20B | |||
| Moderna Inc
MRNA
| Tjmrcntmt | Hzrdt | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Qyyggcwz | Jxp | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Dzlfjjdw | Bddd | $13B |
United States